Jump to main content
Jump to site search

Issue 5, 2015
Previous Article Next Article

Recent discoveries and developments of androgen receptor based therapy for prostate cancer

Author affiliations

Abstract

The main focus of this review is to discuss the discoveries and developments of various therapies for prostate cancer. The AR has played an important role in prostate cancer growth and functions. This review discusses several groups of drugs that have sparingly good anti-cancer activities, as well as a similar structure and behaviour. A recent new-generation AR antagonist, Enzalutamide (MDV3100), has been approved for the treatment of advanced/metastatic prostate cancer. Nonsteroidal antiandrogens represent an important class of molecules acting as either antagonists or agonists. Recently, many therapeutic agents for prostate cancer that target the androgen receptor and reduce prostate tumour growth have been approved. The strong response to this new use of Enzalutamide provides a viable, less toxic alternative to chemotherapy. The current status of prostate cancer drugs are discussed here, but it is evident that considerably more work is needed for improvements in respect to efficacy, reduction of the side effects and treatment strategies.

Graphical abstract: Recent discoveries and developments of androgen receptor based therapy for prostate cancer

Back to tab navigation

Article information


Submitted
17 Sep 2014
Accepted
19 Dec 2014
First published
05 Jan 2015

Med. Chem. Commun., 2015,6, 746-768
Article type
Review Article
Author version available

Recent discoveries and developments of androgen receptor based therapy for prostate cancer

R. Elancheran, V. L. Maruthanila, M. Ramanathan, S. Kabilan, R. Devi, A. Kunnumakara and J. Kotoky, Med. Chem. Commun., 2015, 6, 746
DOI: 10.1039/C4MD00416G

Search articles by author

Spotlight

Advertisements